These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 12949430)
1. Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group. Calais da Silva F; Bono A; Whelan P; Brausi M; Queimadelos M; Portillo J; Kirkali Z; Robertson C Oncology; 2003; 65 Suppl 1():24-8. PubMed ID: 12949430 [No Abstract] [Full Text] [Related]
2. The role of intermittent androgen deprivation in prostate cancer. Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079 [No Abstract] [Full Text] [Related]
3. [Current strategies of intermittent hormone therapy in prostate cancer]. Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677 [TBL] [Abstract][Full Text] [Related]
4. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492 [TBL] [Abstract][Full Text] [Related]
5. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. Niraula S; Le LW; Tannock IF J Clin Oncol; 2013 Jun; 31(16):2029-36. PubMed ID: 23630216 [TBL] [Abstract][Full Text] [Related]
6. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418 [TBL] [Abstract][Full Text] [Related]
7. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say. Printz C Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668 [No Abstract] [Full Text] [Related]
9. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Abrahamsson PA Eur Urol; 2010 Jan; 57(1):49-59. PubMed ID: 19683858 [TBL] [Abstract][Full Text] [Related]
10. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153 [TBL] [Abstract][Full Text] [Related]
11. A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″. Kratiras Z; Konstantinidis C; Skriapas K Int Braz J Urol; 2014; 40(1):3-15; discussion 15. PubMed ID: 24642162 [TBL] [Abstract][Full Text] [Related]
12. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy. Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233 [TBL] [Abstract][Full Text] [Related]
13. Long- or short-term hormones for locally advanced prostate cancer? Brower V J Natl Cancer Inst; 2009 Dec; 101(23):1606-8. PubMed ID: 19910554 [No Abstract] [Full Text] [Related]
14. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL; J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219 [TBL] [Abstract][Full Text] [Related]